Loading...
XSTO
NOVKAN
Market cap3mUSD
Oct 01, Last price  
0.25SEK
Name

Kancera AB

Chart & Performance

D1W1MN
XSTO:NOVKAN chart
P/E
—
P/S
2,151.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
35.11%
Rev. gr., 5y
-66.29%
Revenues
14k
-98.65%
07,069,0003,839,0001,813,000470,000282,000308,000113,000358,0003,216,00090,0001,704,000753,0001,035,00014,000
Net income
-45m
L-31.32%
-7,147,000-18,410,000-33,488,000-7,418,000-15,979,000-19,612,000-22,308,000-56,198,000-45,935,000-36,095,000-47,558,000-45,686,000-52,484,000-64,888,999-44,566,000
CFO
-59m
L+5.14%
-5,644,000-23,214,000-27,081,000-6,638,000-19,105,000-20,658,000-23,103,000-53,541,000-45,043,000-33,286,000-46,046,000-44,125,000-47,562,000-55,672,000-58,531,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kancera AB (publ), a biopharmaceutical firm founded in Solna, Sweden, in 2010, specializes in the development of new treatments for inflammatory disorders and various types of cancer, operating both domestically and internationally. The company's pipeline includes several small molecule drug candidates. KAND567 is presently in a Phase IIa clinical trial, assessing its effectiveness against inflammatory heart disease occurring after a heart attack. Additionally, KAND145 is undergoing a Phase I study with healthy volunteers to establish optimal dosing for cancer therapy, alongside a Phase IIa study specifically targeting ovarian cancer. Kancera's research efforts also encompass HDAC inhibitors for managing nerve inflammation and pain, as well as ROR1 inhibitors for addressing solid tumors and blood-related cancers.
URL
https://kancera.com/
IPO date
Feb 21, 2011
Employees
4
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT